[HTML][HTML] Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal …

F Loupakis, A Ruzzo, L Salvatore, C Cremolini, G Masi… - BMC cancer, 2011 - Springer
Background Molecular predictors of bevacizumab efficacy in colorectal cancer have not
been identified yet. Specific VEGF polymorphisms may affect gene transcription and …

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.

F Loupakis, A Ruzzo, L Salvatore, C Cremolini… - BMC Cancer, 2011 - europepmc.org
Background Molecular predictors of bevacizumab efficacy in colorectal cancer have not
been identified yet. Specific VEGF polymorphisms may affect gene transcription and …

[PDF][PDF] Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

F Loupakis, A Ruzzo, L Salvatore, C Cremolini, G Masi… - 2011 - Citeseer
Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not
been identified yet. Specific VEGF polymorphisms may affect gene transcription and …

[引用][C] Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.

F Loupakis, A Ruzzo, L Salvatore, C Cremolini, G Masi… - BMC CANCER, 2011 - arpi.unipi.it
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from
first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. IRIS IRIS Home Sfoglia …

[PDF][PDF] Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

F Loupakis, A Ruzzo, L Salvatore, C Cremolini, G Masi… - 2011 - researchgate.net
Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not
been identified yet. Specific VEGF polymorphisms may affect gene transcription and …

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

F Loupakis, A Ruzzo, L Salvatore, C Cremolini… - BMC …, 2011 - iris.uniroma1.it
Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not
been identified yet. Specific VEGF polymorphisms may affect gene transcription and …

[PDF][PDF] Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

F Loupakis, A Ruzzo, L Salvatore, C Cremolini, G Masi… - 2011 - academia.edu
Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not
been identified yet. Specific VEGF polymorphisms may affect gene transcription and …

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

F Loupakis, A Ruzzo, L Salvatore, C Cremolini, G Masi… - BMC Cancer, 2011 - go.gale.com
Background Molecular predictors of bevacizumab efficacy in colorectal cancer have not
been identified yet. Specific VEGF polymorphisms may affect gene transcription and …

[引用][C] Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

F Loupakis, A Ruzzo, L Salvatore, C Cremolini, G Masi… - BMC Cancer, 2011 - cir.nii.ac.jp
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from
first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer | CiNii Research CiNii 国立 …

[HTML][HTML] Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

F Loupakis, A Ruzzo, L Salvatore… - BMC …, 2011 - bmccancer.biomedcentral.com
Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identified
yet. Specific VEGF polymorphisms may affect gene transcription and therefore indirectly …